RECURRENT ENDOMETRIAL CLEAR CELL ADENOCARCINOMA
Clinical trials for RECURRENT ENDOMETRIAL CLEAR CELL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT ENDOMETRIAL CLEAR CELL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT ENDOMETRIAL CLEAR CELL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy plus chemo shows promise for Tough-to-Treat endometrial cancer
Disease control OngoingThis study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (paclitaxel and carboplatin) helps people with advanced or recurrent endometrial cancer live longer without their cancer getting worse. About 813 participants with stage III, IV, or recu…
Matched conditions: RECURRENT ENDOMETRIAL CLEAR CELL ADENOCARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 25, 2026 16:43 UTC
-
Engineered virus targets Hard-to-Treat endometrial cancer in early trial
Disease control OngoingThis early-phase trial tests a specially designed virus that may selectively attack cancer cells while sparing healthy ones. The study includes up to 34 people with advanced or recurrent endometrial cancer. The main goal is to find the safest dose and understand side effects, wit…
Matched conditions: RECURRENT ENDOMETRIAL CLEAR CELL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 25, 2026 16:36 UTC